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XBP1Hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) drive cancer through their re-
spective receptors, MET and VEGF receptor 2 (VEGFR2). VEGFR2 inhibits MET by promoting MET dephosphory-
lation. However, whether MET conversely regulates VEGFR2 remains unknown. Here we show that MET
suppresses VEGFR2 protein by inducing its endoplasmic-reticulum-associated degradation (ERAD), via intracrine
VEGF action. HGF–MET signaling in epithelial cancer cells promoted VEGF biosynthesis through PI3-kinase. In
turn, VEGF and VEGFR2 associated within the ER, activating inositol-requiring enzyme 1α, and thereby facilitat-
ing ERAD-mediated depletion of VEGFR2. MET disruption upregulated VEGFR2, inducing compensatory tumor
growth via VEGFR2 and MEK. However, concurrent disruption of MET and either VEGF or MEK circumvented
this, enabling more profound tumor inhibition. Our ﬁndings uncover unique cross-regulation between MET
and VEGFR2—two RTKs that play signiﬁcant roles in tumormalignancy. Furthermore, these results suggest ratio-
nal combinatorial strategies for targeting RTK signaling pathways more effectively, which has potentially impor-
tant implications for cancer therapy.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A number of growth factors and cognate receptor-tyrosine-kinases
(RTKs) display genetic alterations in cancer and contribute to various
aspects of tumor progression (Choura and Rebai, 2011; Takeuchi and
Ito, 2011). Hepatocyte growth factor (HGF), also known as scatter fac-
tor, signals through theRTKMET,mainly to regulate epithelial-cell func-
tions including motility, invasiveness, survival and proliferation
(Gherardi et al., 2012). In contrast, vascular endothelial growth factor
(VEGF), particularly VEGF-A, signals through the RTK VEGFR2, primarily
to regulate endothelial cell activities that facilitate vasculogenesis, an-
giogenesis and vascular function (Carmeliet and Jain, 2011; Ellis and
Hicklin, 2008; Ferrara et al., 2003). Aberrant MET stimulation in tumor
epithelial cells, via activating mutations, gene ampliﬁcation and/or
mRNA and protein overexpression, increases tumor aggressiveness
and correlates with poor prognosis (Gherardi et al., 2012; Sadiq and
Salgia, 2013). On the other hand, VEGF production bymalignant epithe-
lial cells or associated stromal cells enables the formation and mainte-
nance of vascular networks that support tumor growth. Although. This is an open access article underVEGFR2 is expressed most frequently on tumor endothelial cells
(Smith et al., 2010), it can be expressed also by malignant epithelial
cells, and promotes their proliferation—for example, in concertwith sig-
naling by epidermal growth factor receptor (EGFR) (Goel andMercurio,
2013; Lichtenberger et al., 2010). Germline variations in the VEGFR2
gene alter expression of VEGFR2 protein in tumor endothelial and epi-
thelial cells, as well as VEGFR2's involvement in tumor vascularization
(Glubb et al., 2011).
Beyond individual RTK contributions, evidence suggests that crosstalk
betweendifferent RTKs augments tumor growth andpromotes resistance
to conventional or targeted therapies (Chong and Janne, 2013; Engelman
et al., 2007; Wilson et al., 2012). MET interacts functionally with several
RTKs, including EGFR, ERBB2 and IGF-1R (Bauer et al., 2006; Boon et al.,
2002; Engelman et al., 2007; Khoury et al., 2005; Liu et al., 2009;
Yamamoto et al., 2006). EGFR stimulation drives MET phosphorylation
(Yamamoto et al., 2006), while MET-gene ampliﬁcation in lung
cancer cells harboring resistance-conferring EGFR mutations activates
ERBB3–PI3-kinase (PI3K) signaling (Engelman et al., 2007). Combined
EGFR and MET inhibition showed enhanced efﬁcacy against human
NSCLC tumor xenografts in mice (Turke et al., 2010). In a phase II clinical
study, concurrent treatment with the EGFR inhibitor erlotinib and the
anti-MET antibody onartuzumab improved survival as compared to erlo-
tinib monotherapy in a subset of NSCLC patients expressing high tumorthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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did not recapitulate this latter ﬁnding (ASCO 2014). VEGFR2 and MET
also can cross-interact: in glioblastomamultiforme cells, VEGFR2 inhibits
MET phosphorylation through enhanced recruitment of protein tyrosine
phosphatase 1B, thereby suppressing MET-dependent tumor invasive-
ness (Lu et al., 2012). It remains unknown, however, whether MET recip-
rocally regulates VEGFR2—and if so—then how and towhat consequence.
We demonstrate here that MET suppresses VEGFR2 in epithelial cancer
cells expressing both RTKs, through a unique, cell-autonomous mecha-
nism involving intracrine VEGF and endoplasmic reticulum associated
degradation or ERAD. MET disruption upregulates VEGFR2, which drives
compensatory tumor growth. Importantly, this undesired outcome of
MET disruption can be blocked by concurrent inhibition of the MET and
VEGFR2 pathways. Our results underscore the potential of combinatorial
RTK inhibition to enhance anti-tumor efﬁcacy. More speciﬁcally, our data
provide translational strategies for increasing the efﬁcacy of therapeutic
modalities targeting the HGF–MET and VEGF–VEGFR2 pathways in
cancer.
2. Materials and Methods
2.1. Patient Tumor Samples
Formalin-ﬁxed parafﬁn-embedded tissues from 31 non-small cell
lung cancers (9 adenocarcinomas, 3 adenosquamous carcinomas, 13
squamous cell carcinomas and 6 large cell carcinomas) were obtained
from multiple sources (Advanced Bioscience Laboratories, Kensington,
MD; University of Michigan, Ann Arbor, MI; Cureline, South San
Francisco, CA; Cooperative Human Tissue Network, Nashville, TN;
ProteoGenex, Culver City, CA; Cytomix (Origene), Rockville, MD; MT
Group, Van Nuys, CA, USA). Histological diagnosis was conﬁrmed cen-
trally by a pathologist (H.K.).
2.2. Cell lines and Cell Culture
H441, C829, C32, PC-3, H1838 and H2347 were purchased from
ATCC. PSN1, UM-UC-1 and UM-UC-3 cells were purchased from
ECACC. RERF_LC, EBC1 and KP4 were purchased from JHSF. The
NSCLC cell line LKPH4 was derived from a KRasLSL-G12D/+;p53FL/+;Z/
EG lung tumor-bearing mouse. H441 cells were cultured in F12/
DMEM (50:50) with 10% Fetal Bovine Serum and 2 mM L-glutamine.
C829, C32, PC-3, H1838, H2347, PSN1, UM-UCs, RERF_LC, EBC1 and
KP4 were cultured in RPMI 1640 with 10% Fetal Bovine Serum and
2 mM L-glutamine. LKPH4 cells were cultured in DMEM high glucose
with 10% FBS and 2 mM L-glutamine. Cells grown under hypoxia
were incubated for 48 h under an atmosphere of 5% CO2-balanced
N2 to obtain 1% O2 at 37 °C. Otherwise grown under normoxia at
37 °C, 5% CO2.
2.3. Reagents
Recombinant humanVEGF165 andHGFwere generated andpuriﬁed at
Genentech (South San Francisco, CA). Antibodies against human VEGFR2,
phospho-VEGFR2 (Tyr1175), MET, phospho-MET (Tyr1234/1235), Akt,
phospho-Akt (S473), Rab5/8/9, Cbl, Cbl-b, ubiquitin, Gab1, phospho-
Gab1, PLC , phospho-PLC , MEK, phospho-MEK, ERK, phospho-ERK,
phospho-S6, EGFR, PERK, CHOPandBIPwere fromCell Signaling (Beverly,
MA). Anti-ATF6 was from Cosmo Bio Co. (Tokyo, Japan). Antibodies
against phosphotyrosine (4G10) and GAPDHwere fromMillipore (Biller-
ica,MA). Antibodies against actin, tubulin, and VEGFR1were fromAbcam
(Cambridge, MA). Mouse anti-VEGF was from Origene (Rockville, MD).
Rabbit anti-VEGFR2 (N-terminus) was from Cell Sciences (Canton, MA).
FGFR1 antibodywas from Santa Cruz Biotechnology (Santa Cruz, CA). An-
tibodies against ER marker (P4HB/PDI), Golgi marker (GOLGA2), gp78
(AMFR), and HRD1 (SYVN-1) were purchased from Sigma Aldrich (St.
Louis, MO). K48-ubiquitin, XBP-1s, phosphor-IRE1 α antibodies weregenerated and puriﬁed at Genentech. MG132 and Dynasore were from
Calbiochem (La Jolla, CA). Small molecule inhibitors (SMI) against MET
(GDC0712), PI3K (GDC0941), MEK (cobimetinib), JAK (G00043484),
and IRE1α (compound 3 and 4μ8c) were synthesized for Genentech.
SU4312 was from Enzo (Farmingdale, NY). Leupeptin and pepstatin A
were from Sigma Aldrich. E-64d was from Cayman Chemicals (Ann
Arbor, Michigan).
2.4. Mouse Studies
Five million H441.shMet 3.11 cells suspended in HBSS were inoc-
ulated subcutaneously in the right ﬂank of CRL nu/nu mice (Charles
River Laboratories). When tumors reached an average volume of
~250 mm3, mice (8 per group) were treated with either 5% sucrose
water (provided as drinking water, changed weekly) plus MCT
((0.5% [w/v] methylcellulose, 0.2% [w/v] polysorbate 80 [Tween-
80], 0.1 ml, daily, oral gavage), Doxycycline (0.2 mg/ml, dissolved
in 5% sucrose water, changed 3×/week), B20-4.1.1 (anti-VEGF anti-
body, 5 mg/kg, intraperitoneal, 2×/week), or cobimetinib (MEKi,
5 mg/kg, daily orally dosed for the duration of the study), or the com-
bination of Doxycycline plus B20-4.1.1 or Doxycycline plus
cobimetinib. Tumor volumes were measured in two dimensions
(length and width) using Ultra Cal IV calipers (Model 54 10 111;
Fred V. Fowler Company; Newton, MA). The tumor volume was
calculated using the following formula: tumor volume (mm3) =
(length × width2) × 0.5. All procedures were approved by and
conformed to the guidelines and principles set by the Institutional
Animal Care and Use Committee of Genentech and were carried out
in an Association for the Assessment and Accreditation of Laboratory
Animal Care (AAALAC)-accredited facility.
2.5. Generation of Cell Lines Stably Expression Dox-inducible MET shRNA
Two independent MET shRNA were cloned into pHUSH vector as
described (Pai et al., 2008). The sequence used in the studies is as
follows.shMET 3 5′-GATCCCCGAACAGAATCACTGACATATTCAAGAGATATGTC
AGTGATTCTGTTCTTTTTTGGAAA-3′shMET 4 5′-GATCCCCGAAACTGTATGCTGGATGATTCAAGAGATCATCC
AGCATACAGTTTCTTTTTTGGAAA-3′shGFP2 EGFP
shRNA (sense)5′-GATCCCCAGATCCGCCACAACATCGATTCAAGAGATCGAT
GTTGTGGCGGATCTTGTTTTTTGGAAA-3′All constructs were conﬁrmed by sequencing. EGFP control shRNA
was described previously (Pai et al., 2008). The shRNA containing retro-
virus was produced by co-transfecting GP2-293 packaging cells
(Clontech Laboratories, Mountain View, CA) with VSV-G (Clontech Lab-
oratories) and pHUSH-MET shRNA constructs. Viral supernatants were
harvested 72 h after transfection, and cleared of cell debris by centrifu-
gation for transduction.
H441 cells were maintained in F12/DMEM 50/50 medium contain-
ing tetracycline-free FBS (Clontech Laboratories), and transduced with
retroviral supernatant in the presence of 4 μg/ml polybrene. 72 h after
infection, 2 μg/ml puromycin (Clontech Laboratories) was added to
the medium to select stable clones expressing shRNA. Clones were iso-
lated, treated with 0.1 or 1 μg/ml doxycycline (Clontech Laboratories)
for 4 days, and inducible knockdown of MET protein was assessed by
immunoblot analysis. Cell cycle analyses were performed as described
(Pegram et al., 1999).
2.6. Patient-derived Tumor Xenograft Microarray Analysis
Patient-derived lung tumor xenograft samples were analyzed using
Affymetrix Human Genome U133 Plus 2.0 arrays. The Bioconductor
408 T.T. Chen et al. / EBioMedicine 2 (2015) 406–420package affy (Gautier et al., 2004) was used for obtaining RMA-
normalized expression data. For both MET and VEGFR2 a uniquely
mapped probe set was used.
2.7. Immunoblotting and Immunoprecipitation
Cells were lysed in RIPA buffer (50mM Tris, pH 7.4, 150mMNaCl,
1% NP-40, 0.25% sodium deoxycolate, 1 mM EDTA, 1 mM sodium
vanadate, 10 mM ß-glycerophosphate, and protease inhibitors
(Thermo Fisher Scientiﬁc, Pittsburgh PA). To deglycosylate the dena-
tured protein, the sample was treated using either Endoglycosidase
H (Endo H) or peptide N-glycosidase F (PNGaseF; New England
Biolabs, Ipswich, MA) according to the manufacturer recommenda-
tions. Both deglycosylated and untreated samples were subjected
to SDS-PAGE. For immunoprecipitation, cell lysates were further incu-
bated under agitation at 4 °C for 30min, and then centrifuged at 20,000 g
for 30min at 4 °C. Equivalent levels (500 μg) of protein, determined using
the DC protein assay reagent (Bio-Rad Labs, Hercules, CA), were
precleared by anti-Rabbit Ig IP Dynabeads (Life technologies, Grand
Island, NY) and immunoprecipitated overnight at 4 °C with indicated
antibody. Immune complexes were retrieved using anti-Rabbit Ig IP
Dynabeads. Immunoprecipitates were washed three times with same
lysis buffer and then separated by SDS-PAGE. Proteins were transferred
to nylon membranes (Bio-Rad), probed with indicated antibodies, and
detectedusing aChemiDoc™MP Imaging Systemandenhanced chemilu-
minescence (Bio-Rad). After detection, the results were quantiﬁed by
densitometry using ImageJ (NIH, Bethesda, Maryland).
Protein phosphorylation was usually determined by immuno-
blotting as described previously (Luque et al., 2003). VEGFR2 auto-
phosphorylation was analyzed in presence of 100 μM activated sodium
ortho-vanadate (Gordon, 1991) for 24 h at 37 °C. Phospho-VEGFR2
was then analyzed by IP with anti-VEGFR2 followed by immunoblot
with anti-phosphotyrosine antibody, or by sandwich ELISA using the
human phospho-VEGFR2/VEGFR2 Duoset IC kit (R&D). Antibody detec-
tion of K48-linked ubiquitin was performed by IP with anti-K48-
ubiquitin antibody as described previously (Gonzalvez et al., 2012).
2.8. Transfection With siRNA Oligonucleotides
The siRNA oligonucleotides against human VEGFA, VEGFR2, MET,
Cbl, Cbl-b, gp78, HRD1, were from Dharmacon (Lafayette, CO):
Non-targeting control (NTC)1: 5′ CTT ACG CTGAGT ACT TCGA-dTdT
3′
siVEGFA Smartpool: L-003550
siVEGFR2 #1: J-003148-09
siVEGFR2 #2: J-003148-10
siVEGFR2 #3: J-003148-11
siVEGFR2 #4: J-003148-12
siMET Smartpool: L-003156
siCbl Smartpool: L-003003
siCbl-b Smartpool: L-003004
sigp78 Smartpool: L-006522
siHRD1 Smartpool: L-007090
sip97/VCP Smartpool: L-008727.
Cells were transfected using Transfectant #2 (Dharmacon) accord-
ing to the manufacturer's protocol.
2.9. Proximity Ligation Assay (PLA)
H441 cells grown on Lab-TekII chamberslides (Thermo Fisher Scien-
tiﬁc) were incubated in the presence or absence of HGF (100 ng/ml)
overnight at 37 °C in serum-free media. Cells were ﬁxed with 4% para-
formaldehyde for 15 min, with or without permeabilization, blocked,incubated overnight with mouse anti-VEGF (Origene) and rabbit anti-
VEGFR2 (Cell Sciences). Proximity ligation was performed using the
Duolink Detection Kit with PLA PLUS and MINUS Probes for mouse
and rabbit (Olink Bioscience, Uppsala, Sweden) according to the
manufacturer's protocol. Slides were mounted with Prolong Gold anti-
fade reagent with DAPI and examinedwith a Zeiss AxioImager M2 ﬂuo-
rescence microscope under a 63× oil objective, using Slidebook soft-
ware to acquire images. Images were then analyzed and red dots
counted by NIH ImageJ. Eight ﬁelds at 600× were randomly chosen
for analysis and averaged per condition examining four independent
preparations individually.
To counterstain with ER, Golgi, or Rab antibodies, PLA was per-
formed as previously described without mounting; samples were
then incubated with primary anti-ER, anti-Golgi or indicated anti-
Rab antibodies (1:100) at room temperature for 2 h, washed 2
times with PLA wash buffer A and incubated with ﬂuorophore-
linked secondary antibodies at room temperature for 1 h. Samples
were washed again 2 times with PLA buffer A and once with PLA
buffer B. Slides were then mounted with Prolong Gold anti-fade re-
agent containing DAPI and viewed with a LEICA SP5 inverted confo-
cal microscope under a 63× oil objective, using Leica LAS AF software
to acquire images.2.10. Immunocytochemistry and Confocal Microscopy
H441 cells were grown on Lab-TekII chamberslides (Thermo Fisher
Scientiﬁc) and treated as indicated. Cultureswere ﬁxedwith 4% parafor-
maldehyde for 15 min at room temperature and permeabilized with
0.2% saponin in blocking buffer (10% goat serum, 10 mM Hepes,
10 mM glycine in RPMI 1640) for 15 min at room temperature. Slides
were then washed and blocked in blocking buffer for 1 h at room tem-
perature. Indicated antibodieswere diluted in blocking buffer incubated
with cells at 4 °C overnight. After three washes with PBS, cells were in-
cubated with respective 1:100 diluted secondary antibodies conjugated
with either Alexa488 or Alexa647 (Invitrogen). F-actin was detected
using Alexa 555 conjugated phalloidin (Invitrogen) diluted 1:40 in
blocking buffer. Slides were mounted with Prolong Gold anti-fade re-
agent containing DAPI and viewed with a LEICA SP5 inverted confocal
microscope under a 63× oil objective, using Leica LAS AF software to ac-
quire images.2.11. Quantitation of Co-localized Signal
Images were collected randomly (10 images from each treatment; 3
independent experiments), and colocalizationwas determinedwith the
“Colocalization” Plug-in of ImageJ (NIH) with the same color-threshold
settings for all 10 images from each treatment. The co-localized color
channel (blue) and PLA color channel (green) or both red and green
channels (for ICC)were then countedwith the “Analyze particles” com-
mandof Image J. Percent colocalizationwas then calculated by total area
of co-localized channel (blue) over total area of PLA channel (green) or
both red and green channels (for ICC).2.12. VEGF ELISA
To quantify levels of VEGF in the conditioned medium and cell
layers, cells were cultured in complete medium containing 10% FBS at
37 °C until subconﬂuent. Medium containing 0.1% FBS was then added
and collected after 24 h of incubation at 37 °C. The conditionedmedium
was removed and centrifuged at 4 °C for 60 min at 13,200 rpm. The su-
pernatant was then collected and assayed by using a sandwich human
VEGF-ELISA kit (R&D). Cell lysates were collected as above and assayed
by the same kit.
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H441 cells were cultured on a 96-well plate and imaged using a
real-time imaging system (IncuCyte™, Essen Bioscience, Ann Arbor,
Michigan). Frames were captured at 4-h intervals from 2 separate
950 × 760-μm2 regions per well using a 10× objective. Cultures
were maintained at 37 °C throughout and run in sextuplicate. H441
cells conﬂuence was then measured before and after the treatment.
Values from both regions of each well were pooled and averaged
across all 6 replicates.2.14. Statistical Methods
Data and graphwere evaluated using a student's two-tailed t-test or
ANOVAwith GraphPad Prism 6 software (SanDiego, CA). In all analyses,
p b 0.05 was taken to be statistically signiﬁcant.A 
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All work was funded by Genentech, Inc.3. Results
3.1. MET Activity Suppresses VEGFR2
Elevated MET expression is detected in diverse cancer types, includ-
ing ~60% of non-small cell lung carcinomas (NSCLC) (Gherardi et al.,
2012; Sadiq and Salgia, 2013).We veriﬁedMET expression by immuno-
histochemistry (IHC) in both epithelial and endothelial compartments
of NSCLC tumor tissues (Figs. 1A and S1A). To examine VEGFR2 expres-
sion more closely, we ﬁrst analyzed 31 primary NSCLC tumor samples
by VEGFR2 IHC and in-situ hybridization (ISH). While most of the tu-
mors displayed endothelial VEGFR2 expression (data not shown), weB 
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33.3% of adenocarcinomas, though not in squamous cell carcinomas
(Figs. 1B and S1B). We also analyzed mRNA from additional patient-
derived tumors xenografted in mice: 3 of 19 (15.8%) lung adenocarci-
nomas; 1 of 11 (9.1%) lung epidermoid carcinomas; and 1 of 5 (20%)
pleuromesotheliomas showed elevated expression of MET and
VEGFR2 mRNA (Fig. 1C). To identify suitable models for investigating
potential cross-regulation betweenMET andVEGFR2,weﬁrst examined
a panel of epithelial cancer cell lines for mRNA expression of both RTKs
based on microarray analysis (Fig. 1D). We then tested some of these
cell lines for protein expression by immunoblot (Fig. 1E). H441 and
PC3 cells strongly expressed both VEGFR2 and MET, while H1838 and
H2347 expressed lower yet detectable amounts of both proteins. By
contrast, C829 and C32 cells strongly expressedVEGFR2without detect-
able MET, whereas RERF-LC cells expressed no detectable VEGFR2 and
low levels of MET. ISH and IHC analyses conﬁrmed signiﬁcant VEGFR2
expression in H441 cells, albeit at lower abundance than in human um-
bilical vein endothelial cells (HUVEC), with no detectable expression in
HT29 cells (Fig. S1C). Thus, a notable subset of patient-derived tumors
and cancer cell lines exhibits epithelial co-expression of MET and
VEGFR2.
To begin to investigate whether MET regulates VEGFR2, we generat-
ed H441 cell lines harboring a stable, doxycycline (Dox)-inducible MET
shRNA (H441 shMET) (Fig. S1D,E). Untreated H441 cells exhibited con-
stitutive MET phosphorylation, which was inhibited by Dox-induced
MET knockdown or addition of a small molecule inhibitor (SMI) of
MET kinase, GDC0712 (Liederer et al., 2011) (Fig. 1F). Strikingly, MET
knockdown or inhibition substantially increased VEGFR2 protein levels,
without affecting several other RTKs, i.e. VEGFR1, FGFR1 and EGFR
(Figs. 1F and S1D–F). Unlike H441 cells, PC3 cells did not exhibit signif-
icant constitutive MET phosphorylation; however, HGF treatment of
PC3 cells induced MET phosphorylation within 15 min, subsiding by
24 h (Fig. 1G). Conversely to the upregulation of VEGFR2 uponMET dis-
ruption, MET stimulation by HGF caused dramatic depletion of VEGFR2
protein by 24 h (Fig. 1G). Similarly, HGF treatment downregulated
VEGFR2 within 6–24 h in H2347 and H1838 cells, and this suppression
was reversed byMET inhibition (Fig. 1H). In contrast, HGF had minimal
impact on VEGFR2 levels in C829 and C32 cells, which expressed readily
detectable VEGFR2 but littleMET (Fig. 1H). Nevertheless, transfection of
C32 cells with cDNA constructs directing expression of full-length MET
led to dose-dependent suppression of VEGFR2 (Fig. S1G). Thus, consti-
tutive or HGF-induced MET activity suppresses VEGFR2 protein levels
in epithelial tumor cell lines that express both RTKs.
3.2. MET Suppresses VEGFR2 via Intracrine VEGF Action
Previous work indicates that HGF can promote VEGF expression
(Zhang et al., 2003). We therefore examined the possibility that MET
might control VEGFR2 levels via VEGF activity. Untreated H441 cells se-
creted signiﬁcant amounts of VEGF protein into the conditioned culture
media (Fig. 2A). MET inhibitor markedly attenuated VEGF secretion,
whereas HGF treatment increased VEGF amounts by ~2 fold, in a man-
ner thatwas attenuated byMET inhibition. PC3 cells produced lowbase-
line amounts of VEGF, which were unaffected by MET inhibition;
however, HGF treatment upregulated VEGF secretion by ~2.5 fold, andFig. 2.MET suppresses VEGFR2 via PI3K-induced intracrine VEGF action. (A) Effect of HGF (10
H441 cells after 24 h treatment. (B) Effect of MET or VEGFR2 knockdown on VEGF productio
both for 2 days and VEGF protein levels in conditioned media or washed cell monolayers w
H441 cells were subjected to MET inhibition (METi) or knockdown (shMET) and mRNA levels w
ulation of VEGF (D) and VEGFR2 (E) byHGF. PC3 cells were treatedwith PBS or HGF (100 ng/ml
of VEGFR2 or other indicated markers were determined by immunoblot (E). (F and G) Effect o
noblots) in H441 cells. 1× is 1 μM for METi and 10 μM for PI3Ki. (H) Effect of VEGF transfectio
1 μM) in H441 cells. (I) Effect of MET knockdown (shMET) in H441 cells cultured under no
(shMET) or inhibition (METi, 1 μM) on VEGFR2 levels in H441 cells cultured under normoxia or
tralization (anti-VEGF, 10 μg/ml) or VEGF siRNA knockdown (siVEGF) on VEGFR2 modulation
(siNTC) was used as control. Error bars indicate S.E.M for a minimum of three independent exthis increase was attenuated byMET inhibition (Fig. 2A). Further analy-
sis of H441 cells revealed that perturbation of MET, but not VEGFR2, led
to a marked drop in both secreted and cellular VEGF protein pools
(Figs. 2B, S2A and S2B). MET disruption also decreased VEGF mRNA
(Fig. 2C). Thus, MET promotes de novo transcription, biosynthesis and
secretion of VEGF.
We next sought to interrogate whether the induction of VEGF pro-
duction and the suppression of VEGFR2 by MET were mechanistically
linked. Several intracellular RTK signaling cascades, including the
PI3K/AKT, MEK/ERK and JAK/STAT pathways, may regulate VEGF pro-
duction in response to speciﬁc growth factors (Dong et al., 2001; Eder
et al., 2009; He et al., 2006; Jiang et al., 2000; Kowanetz and Ferrara,
2006; Zhang et al., 2010). SMI disruption of PI3K, but not MEK or JAK,
substantially attenuated HGF-induced VEGF production in PC3 cells
(Figs. 2D and S2C). Remarkably, PI3K SMI, but not MEK or JAK SMIs, ef-
ﬁciently blocked VEGFR2 suppression in response to HGF (Fig. 2E). Sim-
ilarly, MET or PI3K SMI exerted dose-dependent attenuation of MET-
driven VEGF production—and coincidently, VEGFR2 suppression—in
H441 cells (Figs. 2F,G and S2D). Thus, MET signaling upregulates VEGF
biosynthesis via the PI3K pathway—an event that correlates with
VEGFR2 depletion. However, a direct causal link between VEGF induc-
tion and VEGFR2 suppression remained to be investigated.
To test whether VEGF induction could downregulate VEGFR2, we
used two gain-of-function strategies. First, ectopic VEGF expression by
cDNA transfection of H441 cells substantially reversed the upregulation
of VEGFR2 upon MET perturbation (Fig. 2H). Second, oxygen depriva-
tion, which drives VEGF production via hypoxia-inducible factor
(HIF)-1α (Forsythe et al., 1996), prevented the drop in VEGF secretion
caused by MET knockdown in H441 cells (Fig. 2I). Moreover, hypoxia
blocked upregulation of VEGFR2 upon MET disruption, and this effect
was reversed by siRNA knockdown of VEGF (Fig. 2J). Hence, either ec-
topic VEGF expression, or—more physiologically—hypoxia-induced pro-
duction of endogenous VEGF, suppresses VEGFR2 protein, supporting a
possible mechanistic role for VEGF.
To address causal involvement of VEGF more directly, we asked
whether its depletion by differentmethods affectsMET-driven suppres-
sion of VEGFR2. Surprisingly, addition of an anti-VEGF antibody, which
neutralized essentially all the detectable extracellular VEGF (Fig. S2E),
had little impact on VEGFR2 upregulation in response toMETdisruption
in H441 cells (Fig. 2K). In contrast, siRNA knockdown of VEGF increased
baseline VEGFR2 levels, but did not further augment VEGFR2 upregula-
tion uponMET disruption (Figs. 2K and S2E). These results indicate that
MET and VEGF operate along the same axis and thatMET-induced VEGF
plays a critical role in VEGFR2 suppression. Furthermore, intracellular
(i.e., intracrine), rather than extracellular (i.e. autocrine or paracrine)
VEGF activity mediates the depletion of VEGFR2. Consistent with this
latter notion, addition of exogenous VEGF to H441 or PC3 cells failed
to alter basal VEGFR2 levels or modulation by MET (Fig. S2F,G), in con-
trast to the marked VEGFR2 downregulation induced by transfected or
hypoxia-induced VEGF (Fig. 2H and J).
Endocytosis plays a key role in VEGFR2 activation by extracellular
VEGF (Chen et al., 2010; Sawamiphak et al., 2010). MET knockdown
or inhibition modestly upregulated cell-surface levels of VEGFR2, as in-
dicated by FACS and subcellular fractionation analyses (Fig. S2H,F).
However, disruption of clathrin-mediated endocytosis with the0 ng/ml), METi (GDC-0712, 1 μM) or combinations thereof on VEGF secretion by PC3 and
n. H441 cells were subjected to knockdown of MET (shMET) or VEGFR2 (siVEGFR2) or
ere measured by ELISA. (C) Effect of MET disruption on mRNA levels of MET and VEGF.
ere determined by qPCR. (D and E) Effect of 1 μMof MET, PI3K, MEK, or JAK SMI onmod-
) for 24 h and VEGF levels inwashed cell layerswere determined as above (D), while levels
f MET SMI (F) or PI3K SMI (G) on secreted levels of VEGF (bar graphs) or VEGFR2 (immu-
n on VEGFR2 modulation by MET shRNA knockdown (shMET) or kinase inhibition (METi,
rmoxia or hypoxia on VEGF levels in washed cell layers. (J) Effect of MET knockdown
hypoxia with or without siRNA knockdown of VEGF. (K) Effect of extracellular VEGF neu-
by MET knockdown (shMET) or inhibition (METi, 1 μM) in H441 cells. Scrambled siRNA
periments. *p b 0.05, **p b 0.01, and ***p b 0.005 for indicated comparisons.
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(Fig. S2I), supporting the independence of this function from extracellu-
lar VEGF. Together, these results indicate that MET suppresses VEGFR2
via intracellular action of VEGF.
3.3. MET Induces Intracellular Interaction of VEGF and VEGFR2
The implication of intracellular VEGF in VEGFR2 depletion suggested
that the two proteins might interact within HGF-stimulated and/or
MET-active cells. To address this possibility, we ﬁrst validated suitable
antibodies for detection of intracellular VEGF andVEGFR2 under various
conditions (Fig. S3A–C). Next, we used these antibodies to determine
the relative cellular distribution of the two proteins by immunoﬂuores-
cence. Upon HGF treatment of PC3 cells, VEGF and VEGFR2 displayed
signiﬁcant intracellular co-localization (Fig. 3A). VEGF also showed
marked co-localization with the speciﬁc ER marker P4HB/PDI, but
not the Golgi marker GOLGA2 (Fig. 3B). To investigate whether VEGF
and VEGFR2 directly interact with each other, we used a DNA-
oligonucleotide-based proximity-ligation assay (PLA), in which detec-
tion of two proteins generates an immunoﬂuorescence signal only if
they are within a few nanometers of each other (Soderberg et al.,
2006). PLA analysis of PC3 cells showed that HGF treatment induced
an intracellular interaction between VEGF and VEGFR2 (Fig. 3C); the
PLA signal increased in permeabilized, but not non-permeabilized, cells,
indicating that the two proteins associated with each other within the
cells. HGF-induced VEGF:VEGFR2 complexes coincided with P4HB, but
not GOLGA2 (Fig. 3D). Importantly, the intracellular co-localization of
VEGF and VEGFR2 was unabated by addition of anti-VEGF antibody
(Fig. S3D), demonstrating that this interactionwas independent from ex-
tracellular VEGF. PLA counterstaining with antibodies against certain Rab
proteins to mark speciﬁc intracellular vesicular compartments revealed
HGF-driven VEGF:VEGFR2 association in conjunction with Rab8, but
not Rab5 or Rab9 (Figs. 3E, S3E,F). Thus, HGF induces interaction be-
tween VEGF and VEGFR2 at the ER, perhaps during or after parallel fold-
ing or maturation of the two newly synthesized proteins. Additional
interaction is detected in Rab8-positive secretory vesicles, suggesting
some anterograde transport of the complex from the ER toward the
Golgi compartment.
3.4. MET Drives Phosphorylation, K48 Ubiquitination and Degradation of
VEGFR2
We next investigated whether the intracellular VEGF–VEGFR2 asso-
ciation in response to HGF might lead to post-translational modiﬁca-
tions of VEGFR2. Unlike VEGF, which promoted signiﬁcant VEGFR2
phosphorylation in H441 cells within 10–15 min of exposure, HGF did
not drive rapid VEGFR2 phosphorylation (data not shown). However,
a 24-h exposure to either VEGF or HGF induced a signiﬁcant increase
in VEGFR2 phosphorylation, as detected by anti-phospho-tyrosine IB
analysis of VEGFR2 IP (Fig. 4A), or a more sensitive sandwiched-ELISA
technique (see Supplemental Experimental Procedures) (Fig. 4B and
C). Addition of anti-VEGF antibody, which blocked VEGFR2 phosphory-
lation in response to exogenous VEGF, did not signiﬁcantly inhibit
VEGFR2 phosphorylation in response to HGF in H441 or PC3 cells
(Fig. 4B and C). In contrast, siRNA knockdown of VEGF attenuated
HGF-induced VEGFR2 phosphorylation (Fig. 4B and C). These results
suggest that intracrine VEGF activity induced by HGF drives phosphory-
lation of VEGFR2.
Biosynthesis of transmembrane proteins such as VEGFR2 typically
involves partial N-linked glycosylation in the ER, followed by further
modiﬁcation and elaboration of the N-linked sugars in the Golgi com-
partment. To examine which pool of VEGFR2 is subjected to MET-
driven suppression, we treated cell lysates with Endoglycosidase H
(Endo H), which cleaves only immature N-glycans, or Peptide-N-
Glycosidase F (PNGaseF), which cleaves all N-glycans. Undigested
VEGFR2 migrated as two major protein bands—representing partiallyand fully glycosylated VEGFR2—both of which were enriched upon
MET disruption (Fig. 4D). Endo H treatment completely depleted the
partially glycosylated VEGFR2 band, giving rise to a lower-MW band
representing deglycosylatedVEGFR2 (Fig. 4D); in contrast, PNGaseF treat-
ment collapsedboth bands into thedeglycosylated formofVEGFR2. These
results suggest that MET suppression operates at the level of the ER-
associated pool of partially glycosylated VEGFR2 polypeptides.
At the cell surface, VEGF-induced phosphorylation of VEGFR2 leads
to receptor internalization, ubiquitination and proteasomal degradation
(Duval et al., 2003), or alternatively, recycling to the plasmamembrane
through a VE-cadherin linked pathway (Gavard andGutkind, 2006).We
reasoned that the suppression of VEGFR2 by MET also might entail
proteasomal degradation—a process frequently involved in RTK modu-
lation (Bonifacino andWeissman, 1998). Indeed, the proteasome inhib-
itor MG132, but not a lysosome-inhibitor cocktail containing leupeptin,
pepstatin A and E-64 (LPE), nor the anti-VEGF antibody, blocked
VEGFR2 suppression in response to HGF, stabilizing the Endo H-
sensitive ER pool of VEGFR2 protein (Figs. 4E and S4A).
Lysine 48 (K48)-linked ubiquitination of protein substrates typically
precedes their proteasomal destruction (Bonifacino and Weissman,
1998). We therefore examined whether VEGFR2 is thus ubiquitinated.
IP of VEGFR2 under denaturing conditions (to strip away non-
covalently attached proteins), followed by a K48-ubiquitin-speciﬁc IB,
revealed constitutive baseline K48 ubiquitination of VEGFR2 in H441
cells (Figs. 4F and S4B). The K48-ubiquitinated fraction of VEGFR2 in-
creased with MG132, and rose further in response to HGF alone or
HGF plus MG132; in contrast, exogenous VEGF only minimally impact-
ed this modiﬁcation (Fig. 4F). In agreement with other ﬁndings (Ewan
et al., 2006), the shift in gel migration of VEGFR2 suggested conjugation
of 1–2 ubiquitin moieties. Importantly, HGF treatment increased K48
ubiquitination of VEGFR2 while decreasing total VEGFR2, whereas
MET knockdown blocked K48 conjugation while increasing total
VEGFR2 (Fig. 4G). Deubiquitinase treatment of VEGFR2 IPs from H441
and PC3 cells diminished the amount of K48 ubiquitin detected
(Fig. S4B,C), further conﬁrming HGF-induced K48 ubiquitination of
VEGFR2. Previous work identiﬁes the E3 ubiquitin ligase Cbl as respon-
sible for VEGFR2 ubiquitination in endothelial cells in response to extra-
cellular VEGF (Duval et al., 2003; Ewan et al., 2006). However, siRNA
knockdown of Cbl, or its relative Cbl-b, which signiﬁcantly depleted
each target protein, did not affect the baseline level of VEGFR2 or its up-
regulation by MET knockdown in H441 cells (Fig. S4D,E). Thus, unlike
extracellular VEGF, MET promotes Cbl- and Cbl-b-independent K48
ubiquitination of VEGFR2. Whether MET-driven phosphorylation of
VEGFR2 is a pre-requisite for its K48 ubiquitination and degradation re-
mains to be investigated.3.5. MET Depletes VEGFR2 via IRE1α-supported ERAD
Based on the above ﬁndings, we reasoned that the process known as
ER-associated degradation (ERAD) (Vembar and Brodsky, 2008) might
be involved in the depletion of VEGFR2 in response to MET activity. Al-
though ERAD constitutively eliminates misfolded or aggregated poly-
peptides from the ER, it has been implicated also in modulating basal
cellular levels of certain proteins (Hirsch et al., 2009). The E3 ligases
HRD1 and gp78 as well as the chaperone p97/VCP play important
roles in ERAD-mediated disposal of soluble and transmembrane protein
substrates (Bernasconi et al., 2010; Vembar and Brodsky, 2008; Hirsch
et al., 2009). Strikingly, siRNA knockdown of HRD1, gp78, or VCP sub-
stantially reversed VEGFR2 suppression by HGF in both PC3 and H441
cells (Figs. 5A and S5A–E). Furthermore, knockdown of HRD1 and
gp78, but not Cbl, decreased the ratio of K48-ubiquitinated over total
VEGFR2 protein in PC3 cells—both before and after treatment with
HGF—reversing HGF-induced VEGFR2 suppression (Figs. 5B and S5F).
Thus, E3 ligases that support ERAD are required for K48 ubiquitination
and proteasomal degradation of VEGFR2 in response to MET signaling.
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Fig. 3.HGF induces intracellular association of VEGF and VEGFR2. (A and B) H441 cells were treated with vehicle or HGF (100 ng/ml) for 24 h, ﬁxed and stained for immunoﬂuorescence
with anti-VEGF (green), anti-VEGFR2 (red) andDAPI (Nucleus, blue) (A), or anti-VEGF (green), anti-ER or Golgimarker (red), andDAPI (blue) (B). VEGF colocalizationwith VEGFR2, ER or
Golgi was quantitated (B, right panel). Nuclear stain is DAPI (blue). Error bars indicate S.E.M., n = 3; **p b 0.01; *p b 0.05 for indicated comparisons. (C) Cells were treated as above, and
analyzed by proximity ligation assay (PLA) with quantiﬁcation (right) with or without permeabilization. Red dots denote regions of signal ampliﬁcation for VEGF:VEGFR2 proximity liga-
tion. Nuclear stain is DAPI (blue). Error bars indicate S.E.M., n = 4; ***p b 0.005; *p b 0.05 for indicated comparisons. (D) Cells were treated as in (C), permeabilized, and PLA was coun-
terstainedwith either the ERmarker (top) or Golgimarker (bottom). Green dots denote VEGF:VEGFR2 association. ER or Golgi stain is red and nuclear stain is blue. Colocalization between
PLA signal and ER or Golgi staining is quantiﬁed (right). Error bars indicate S.E.M., n = 3; *p b 0.05, arrows denote colocalized signal. (E) Cells were treated as above and PLA (green) was
counterstained with indicated anti-Rab antibody (red), with nuclear stain (blue). Colocalization between PLA and Rab signals was quantiﬁed as in (D). Error bars indicate S.E.M., n = 3;
**p b 0.01 for indicated comparison.
413T.T. Chen et al. / EBioMedicine 2 (2015) 406–420The ERAD machinery is maintained and modulated by the unfolded
protein response (UPR) (Brodsky, 2012; Hetz and Glimcher, 2009;
Walter and Ron, 2011). Inositol-requiring enzyme 1α (IRE1α)—a key
component of the UPR—activates the transcription factor X box protein-1 spliced (XBP-1s) to turn on multiple ERAD-linked genes in response
to ER stress. Remarkably, HGF treatment of PC3 cells, which are more re-
sponsive to HGF than H441 cells, induced a time-dependent, biphasic in-
crease in XBP-1s protein, and thiswas further enhanced by knockdownof
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414 T.T. Chen et al. / EBioMedicine 2 (2015) 406–420HRD1and gp78 in conjunctionwith stabilization of VEGFR2 (Fig. 5C). HGF
also upregulated IRE1α phosphorylation, alongwith other UPR activation
markers, namely ATF6 and BIP, but not PERK or its target C/EBP-
homologous protein (CHOP) (Fig. S5G). SMI blockade of either IRE1α ki-
nase (Wang et al., 2012) or RNase (Cross et al., 2012; Lu et al., 2014), but
not PERK inhibition (Axten et al., 2012), attenuated XBP-1s upregulation
by HGF (Figs. 5D, S5H,I), conﬁrming a requirement for IRE1α activity.
Thus, MET activity suppresses VEGFR2 via the ERAD machinery, which
is supported by IRE1α activation.
Since both theVEGF andVEGFR2 polypeptides fold in the ER,we rea-
soned that their association within this organelle might drive theobserved activation of IRE1α. Supporting this, SMI blockade of the
PI3K/AKT pathway, which inhibited HGF-induced VEGF biosynthesis
(Fig. 2D and G), substantially attenuated HGF-dependent upregulation
of XBP-1s, as well as VEGFR2 depletion (Fig. 5E). Furthermore, siRNA
knockdown of VEGF and VEGFR2 also attenuated generation of XBP-1s
in response to HGF (Fig. 5F). In contrast, prolonged exposure to exoge-
nous VEGF did not lead to generation of XBP-1s or degradation of
VEGFR2, as compared to HGF exposure (Fig. S5J). Together, these results
suggest that the HGF/MET-induced intracellular interaction between
VEGF and VEGFR2 triggers IRE1α-supported, ERAD-mediated VEGFR2
disposal.
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415T.T. Chen et al. / EBioMedicine 2 (2015) 406–4203.6. VEGFR2 Drives Compensatory Proliferation, Circumvented by Blockade
of the MET and VEGFR2 Pathways
To interrogate the potential biological outcome of VEGFR2 modula-
tion by MET, we measured possible changes in cell growth. H441 cells
exhibited an increase of ~40% in number over a 3-day culture in
serum-free medium, and MET knockdown or inhibition attenuated
this growth by 2–3 fold (Fig. 6A). siRNA knockdown of VEGF or SMI
blockade of PI3K also attenuated proliferation, and each treatment
further increased the growth inhibition afforded by MET disruption.
In contrast, anti-VEGF antibody did not affect cell growth either at base-
line or upon MET perturbation. These results suggested that PI3K-
dependent signaling and intracrine VEGF activity account for part of
the observed MET-driven proliferation. Consistent with this, knock-
down of either MET or VEGF downregulated intracellular VEGF, while
combined knockdown of both targets led to a further drop in VEGF
levels (Fig. 6B). MET knockdown increased not only total VEGFR2 pro-
tein, but also phosphorylated VEGFR2 (Fig. 6C), suggesting elevated
VEGFR2 activity. Given that MET knockdown downregulated both the
intracellular and secreted VEGF pools, this increase might reﬂect
ligand-independent VEGFR2 autophosphorylation. Importantly, com-
bined knockdown ofMET and VEGFR2 led to stronger growth inhibition
than didMET knockdown alone (Fig. 6D). Thus, increased VEGFR2 activ-
ity drives signiﬁcant compensatory growth in the context of MET
perturbation.In keeping with previous data (Chaudhuri et al., 2011), MET disrup-
tion decreased phosphorylation of MET and its downstream mediators
Gab1, PLC , and AKT; however, phosphorylation of MEK and ERK
increased (Fig. 6E). SMI blockade of VEGFR2 attenuated the increase in
MEK and ERK phosphorylation, whereas PI3K blockade did not
(Fig. 6F). MET inhibition also augmented ERK phosphorylation in
H2347 and LKPH4 cells, and this was reversed by VEGFR2 knockdown
or inhibition (Fig. S6A,B). Given that PI3K inhibition prevents VEGF in-
duction, these data raise the possibility that activation of the MEK–
ERK pathway in the context of MET disruption may be mediated by
VEGF-independent autophosphorylation of VEGFR2. Nevertheless,
MET knockdown, which markedly upregulated VEGFR2, also increased
cellular responsiveness to exogenous VEGF, as evident by signiﬁcantly
higher VEGFR2 phosphorylation as well as proliferation in response to
VEGF addition (Fig. 6G and H). Moreover, whereas exogenous VEGF in-
duced only a modest increase in baseline H441 cell growth, it increased
proliferation more signiﬁcantly in the context of MET knockdown
(Figs. 6H and S6C). These results suggest that VEGFR2 upregulation
upon MET disruption promotes compensatory MEK/ERK phosphoryla-
tion and proliferation via autophosphorylation of VEGFR2, as well as in-
creases responsiveness to extracellular VEGF. Supporting this, SMI
blockade of PI3K did not signiﬁcantly alter VEGF-induced growth of
MET-depleted cells, whereas MEK inhibition completely blocked prolif-
eration (Fig. 6H). Furthermore, concurrent SMI blockade of MET and
MEK had a stronger growth-inhibitory effect than did either SMI alone
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Fig. 6. VEGFR2 upregulation uponMET disruption facilitates compensatory cell growth. (A) Effect of MET or VEGF knockdown on cell growth. H441 cells were subjected to knockdown of
MET (shMET) or VEGF (siVEGF) for 48 h and analyzed at 72 h for growth under the indicated treatment. (B) VEGF concentration in whole cell lysates from (A). (C) H441 cells were sub-
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alyzed by IP and immunoblot. (D) H441 cells were subjected to knockdown ofMET (shMET) or VEGFR2 (siVEGFR2) or both and analyzed for growth as in A. Error bars indicate S.E.M., n=
3; **p b 0.01 for indicated comparison. (E) Effect of MET disruption on VEGFR2 levels and on downstream signaling. H441 cells were treated with or without shMET or METi (GDC-0712,
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416 T.T. Chen et al. / EBioMedicine 2 (2015) 406–420(Fig. 6I and J). Moreover, VEGF knockdown on top ofMET disruption led
to an increase in VEGFR2 protein and enhanced VEGFR2 phosphoryla-
tion in response to exogenous VEGF (Fig. S6D,E). Thus, VEGFR2 upregu-
lation restricts the growth inhibition afforded by MET disruption,
particularly in the presence of extracellular VEGF.
In vivo, extracellular VEGF is often abundantly present in tumors. We
reasoned that this might limit the effectiveness of MET-disruptive thera-
py, by driving compensatory growth via the upregulated VEGFR2. To in-
vestigate this, we xenografted H441 cells subcutaneously into mice andallowed them to establish tumors of ~200 mm3. In vehicle-treated mice,
tumors grew to ~1400 mm3 over a period of ~50 days (Fig. 7A). Dox-
inducedMET knockdown or treatment with a neutralizing anti-VEGF an-
tibody (B20.4.1.1) each attenuated growth of the pre-established tumors
by ~50% (mean tumor volume 1360 mm3, control, 840 mm3, Dox,
760mm3, anti-VEGF). Remarkably however, a combination of both inter-
ventions led to a complete inhibition of tumor growth. In contrast, Dox
treatment of H441 xenografts harboring a GFP shRNA as a control did
not alter tumor growth or the inhibition thereof by anti-VEGF antibody
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alyzed end-of-study tumor samples by IB for levels of VEGFR2 andMET or
by ELISA for levels of epithelial-derived human (h) VEGF. Dox treatment
of H441 tumors harboring MET shRNA induced a substantial METknockdown, strongly inhibiting MET phosphorylation; MET perturbation
was associated with marked upregulation of VEGFR2 protein (Fig. 7B),
and decreased the available amount of hVEGF in tumors by approximate-
ly onehalf (Fig. 7C). In contrast, anti-VEGF treatment only slightly affected
418 T.T. Chen et al. / EBioMedicine 2 (2015) 406–420VEGFR2 levels, but depleted most of the free tumor-associated hVEGF
(Fig. 7B and C). Furthermore, in an independent study, combined MET
perturbation and MEK inhibition also led to complete attenuation of
tumorgrowth,whereas eachmonotherapy enabledonly partial inhibition
(Fig. 7D and E). IB analysis of end-of-study tumor samples revealed that
MET disruption inhibited AKT phosphorylation while upregulating
VEGFR2 and inducing ERKphosphorylation; on the other hand,MEK inhi-
bition attenuated phosphorylation of ERK but not AKT, whereas com-
bined perturbation of MET and MEK blocked both phosphorylation
events (Fig. 7F and G). Consistent with the enhanced growth inhibition
of H441 tumors, combined inhibition of MET and MEK also led to signiﬁ-
cantly greater inhibition of growth of LKPH4 and PC3 cells in 2D or 3D
in vitro cultures, respectively (Fig. S7B–E). Together, these results suggest
that VEGFR2 upregulation upon MET disruption facilitates compensatory
tumor growth in response to residual VEGF in tumors. Importantly, con-
current inhibition of either MET and VEGF or MET and MEK circumvents
this compensation and provides signiﬁcantlymore profound inhibition of
tumor growth.
4. Discussion
RTK pathways often regulate one another, and crosstalk between
speciﬁc RTKs facilitates not onlymalignant tumor growth, but also resis-
tance to cancer therapy.While epithelial signaling by HGF-MET primar-
ily controls cell migration and invasiveness, there is evidence that MET
also drives cell proliferation (Gherardi et al., 2012). The role of VEGF and
VEGFR2 in modulating tumor-vascular growth and function is well
established, both in preclinical models and in cancer patients (Ellis and
Hicklin, 2008). Additionally, in tumor epithelial cells, the VEGF–VEGFR2
pathway can cooperate with EGFR signaling to promote proliferation
(Lichtenberger et al., 2010). In contrast, in glioblastoma multiforme,
VEGFR2 counteractsMET signaling and tumor invasiveness by facilitating
MET dephosphorylation (Lu et al., 2012). Much less is known, however,
about potential interactions between the VEGF–VEGFR2 and HGF–MET
pathways in epithelial cancer cells and the resulting impact on tumor
growth. Given this paucity of data, and the strong implication of both
the VEGF–VEGFR2 and HGF–MET cascades as therapeutic targets in
NSCLC, we were interested in ﬁnding out whether these two RTK
pathways might interact in epithelial cancer cells in a biologically
meaningful manner. Our studies reveal that MET signaling sup-
presses VEGFR2 activity in cell lines that express both RTKs. HGF–
MET signaling via PI3K exerts negative control over VEGFR2 through
a cell-autonomous mechanism that involves intracrine VEGF action
and consequent ERAD-mediated depletion of VEGFR2 (Fig. 7H). In
contrast, MET disruption upregulates VEGFR2, which facilitates com-
pensatory tumor-cell proliferation (Fig. 7I). This unintended out-
come limits the efﬁcacy of MET-disrupting monotherapy; further
proliferation may also be driven by aberrant mutational activation
of the RAS–MEK pathway. However, compensatory growth can be
circumvented by combined disruption of the MET and VEGFR2 or
MET and MEK pathways to achieve complete suppression of tumor
growth. Given the role of PI3K in VEGF upregulation, it is possible
that a similar combinatorial strategywould enhance anti-tumor activity
of PI3K inhibitors, as is the case for MET inhibitors.
Consistent with previous data (Bonnesen et al., 2009; Carrillo de
Santa Pau et al., 2009), we observed endothelial VEGFR2 expression in
most of the 31 NSCLC primary tumors analyzed. We also detected epi-
thelial mRNA and protein expression of VEGFR2 in a small yet signiﬁ-
cant subset of lung adenocarcinomas. Further microarray analysis of
patient-derived tumor samples showed elevated MET and VEGFR2 co-
expression in additional lung cancer subsets. Given the substantial prev-
alence, morbidity and mortality of lung-associated malignancy, this
fraction may represent a considerable number of patients. As MET-
disruptive therapies progress through clinical studies, it is important
to deﬁne how HGF–MET signaling interacts with other RTK pathways,
e.g., VEGF–VEGFR2.Our ﬁndings uncover an unprecedented mechanism of cross-
regulation between two RTKs (Fig. 7H and I). Taken together, the data
demonstrates that MET suppression of VEGFR2 requires PI3K-
mediated biosynthesis of VEGF and intracrine VEGF activity. Several
lines of evidence support this conclusion. First, VEGFR2 depletion re-
quired VEGF and could be induced by transfected or hypoxia-induced
VEGF; however, it was independent of, and not stimulated by, extracel-
lular VEGF. Second, inhibition of clathrin-mediated endocytosis with
dynasore did not perturb MET modulation of VEGFR2. Third, HGF–
MET signaling induced PI3K-dependent VEGF production and intracel-
lular interaction between VEGF and VEGFR2 in conjunction with the
ER. Associationwith vesicular structures marked by Rab8 also occurred,
suggesting that some VEGF–VEGFR2 complexes may escape the ER
toward the Golgi compartment. Fourth, MET disruption stabilized the
Endo H-sensitive form of VEGFR2, which represents the partially glyco-
sylated ER pool of the protein. Fifth, HGF addition, but not exogenous
VEGF, promoted K48 ubiquitination of VEGFR2 and its proteasomal deg-
radation. These data demonstrate an intracellular interaction of VEGF
and VEGFR2, which may trigger the depletion of VEGFR2.
Extracellular VEGF binding induces internalization of VEGFR2 (Ewan
et al., 2006), which appears to be important for efﬁcient signaling (Chen
et al., 2010; Sawamiphak et al., 2010). Moreover, exogenous VEGF in-
duces ubiquitination of VEGFR2 via the E3 ligase Cbl, leading to
proteasomal degradation of VEGFR2 (Duval et al., 2003). This destruction
mechanism is unusual, given that most plasma membrane-bound RTKs
undergo lysosomal rather than proteasomal degradation (Bonifacino
andWeissman, 1998). Our data demonstrates that in contrast to extracel-
lular VEGF, HGF–MET signaling induces K48 ubiquitination and depletion
of VEGFR2 independently of Cbl or Cbl-b yet depending on the ERAD-
associated E3 ligases HRD1 and gp78 and the chaperone p97 (VCP)
(Bernasconi et al., 2010; Hirsch et al., 2009). HGF–MET activated IRE1α
and its downstream transcriptional effector, XBP-1s—a UPR pathway
crucial for ERAD maintenance—and this event was blocked by knock-
down of VEGF and VEGFR2. Together, these results raise the intriguing
hypothesis that interaction of newly synthesized VEGF and VEGFR2
proteins within the ER triggers activation of IRE1α and XBP-1s, thereby
facilitating ERAD-mediatedK48 ubiquitination andproteasomal dispos-
al of VEGFR2. Supporting this, SMI blockade of IRE1α or XBP-1s
prevented VEGFR2 suppression in response to HGF–MET signaling.
Whether intracellular VEGF–VEGFR2 interaction requires VEGFR2 di-
merization, and how this interaction drives IRE1α activation and
ERAD remains to be investigated. One idea is that the massive upregu-
lation of VEGF biosynthesis by HGF–MET signaling overwhelms ER
folding capacity, thereby causing a premature, aberrant interaction be-
tween VEGF and VEGFR2. This may disrupt further maturation, leading
to accumulation of misfolded VEGFR2 protein and its disposal via ERAD.
Conceivably, VEGF degradation also could occur under such circum-
stances, but sufﬁcient VEGF may escape these events to achieve secre-
tion. It is notable in this context that the level of VEGF expressed by
epithelial cancer cells is much higher than that produced by endothelial
cells; moreover, although MET knockdown increased VEGFR2 phos-
phorylation in HUVEC, it did not signiﬁcantly alter total VEGFR2 levels
(data not shown). Thus, the low amount of VEGF expressed by HUVEC
may be insufﬁcient to suppress VEGFR2 at baseline, which would pre-
clude endothelial VEGFR2 upregulation uponMET knockdown. Regard-
less, our data in epithelial cells uniquely identify a cell-autonomous
mechanism that mediates cross-regulation not only between two dis-
tinct RTKs but also concerning a growth factor and its cognate receptor.
Intracrine VEGF signaling was ﬁrst proposed on the basis of evidence
that wildtype, but not VEGF-null, endothelial cells exhibit VEGFR2
phosphorylation in the absence of exogenous VEGF; VEGFR2 phosphor-
ylation was suppressed by VEGFR2 SMI, but not by anti-VEGF antibody,
and was found to be crucial for vascular homeostasis (Lee et al., 2007).
Further evidence supporting intracrine VEGF activity suggested that in-
tracellular activation by VEGFR2 after the receptor is internalized and
trafﬁcked away from the plasma membrane is important for arterial
419T.T. Chen et al. / EBioMedicine 2 (2015) 406–420morphogenesis (Lanahan et al., 2010). Our data show that intracrine
VEGF function can be regulated byMET signaling and plays a signiﬁcant
role in controlling VEGFR2 and associated growth of epithelial cancer
cells.
In conclusion, our studies uncover a unique mechanism of cross-
regulation between two RTKs that play crucial roles in tumormalignan-
cy. Through thismechanism,MET suppresses VEGFR2 levels by promot-
ing proteasomal degradation of VEGFR2. VEGF-blocking agents
have established clinical utility in the treatment of NSCLC adenocarcino-
ma and of certain other epithelial cancers. Furthermore, several MET-
disrupting agents, including antibodies and SMIs, are currently in NSCLC
clinical trials.We found thatMET disruption upregulates VEGFR2, thereby
augmenting compensatory proliferation. Cell growth in the context of
MET perturbation is driven both by VEGF-independent autophosphoryla-
tion of VEGFR2 and enhanced VEGFR2 signaling in response to extracellu-
lar VEGF, which activates of the MEK–ERK pathway (Fig. 7H and I). In
vivo, MET perturbation in tumor epithelial cells is associated with a
marked VEGFR2 upregulation; residual VEGF protein is detected in
tumors and appears to drive further growth. Disruption of either MET,
or VEGF, or MEK slowed tumor progression only partially; however,
combined inhibition of MET and VEGF or MET and MEK completely
blocked tumor growth. Theseﬁndings have potentially important transla-
tional implications, particularly for tumors that display signiﬁcant co-
expression of MET and VEGFR2 in the malignant epithelial cell compart-
ment. In such cases, the effectiveness of HGF–MET-disrupting monother-
apy (or even its combination with other agents not targeting the VEGF–
VEGFR2 pathway) may be offset by reactive growth driven by VEGFR2
upregulation and enhanced VEGF responsiveness. A promising strategy
to overcome these limitations is to disrupt both RTK pathways together
either at the ligand-receptor level or downstream.
Conﬂict of Interest
TC, JP, SM, HK, MM and AA are currently full-time employee of
Genentech (a member of the Roche group). SM, MM and AA own
stock shares of Roche, Inc. All authors declare no competing ﬁnancial
interests.
Acknowledgments
The authors thank Chris Servin and Jun Li for technical assistance,
Jean-Michel Vernes, and Gloria Meng for ELISA consultation, Cecile
Chalouni, Meredith Sagolla and László Kömüves for microscopy assis-
tance, Linda Rangell and Murat Yaylaogle for IHC support, Klara Totpal
for providing cancer cells to support in vivo studies, and Weilan Ye
and members of the Ashkenazi lab for protocols, suggestions and
discussions.
Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.03.021.
References
Axten, J.M., Medina, J.R., Feng, Y., Shu, A., Romeril, S.P., Grant, S.W., Li, W.H., Heerding,
D.A., Minthorn, E., Mencken, T., Atkins, C., Liu, Q., Rabindran, S., Kumar, R., Hong,
X., Goetz, A., Stanley, T., Taylor, J.D., Sigethy, S.D., Tomberlin, G.H., Hassell, A.M.,
Kahler, K.M., Shewchuk, L.M., Gampe, R.T., 2012. Discovery of 7-methyl-5-(1-
{[3-(triﬂuoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-
pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective ﬁrst-in-
class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase
(PERK). J. Med. Chem. 55, 7193–7207.
Bauer, T.W., Somcio, R.J., Fan, F., Liu, W., Johnson, M., Lesslie, D.P., Evans, D.B., Gallick, G.E.,
Ellis, L.M., 2006. Regulatory role of c-Met in insulin-like growth factor-I receptor-
mediated migration and invasion of human pancreatic carcinoma cells. Mol. Cancer
Ther. 5, 1676–1682.Bernasconi, R., Galli, C., Calanca, V., Nakajima, T., Molinari, M., 2010. Stringent require-
ment for HRD1, SEL1L, and OS-9/XTP3-B for disposal of ERAD-LS substrates. J. Cell
Biol. 188, 223–235.
Bonifacino, J.S., Weissman, A.M., 1998. Ubiquitin and the control of protein fate in the se-
cretory and endocytic pathways. Annu. Rev. Cell Dev. Biol. 14, 19–57.
Bonnesen, B., Pappot, H., Holmstav, J., Skov, B.G., 2009. Vascular endothelial growth factor
A and vascular endothelial growth factor receptor 2 expression in non-small cell lung
cancer patients: relation to prognosis. Lung Cancer 66, 314–318.
Boon, E.M., Van Der Neut, R., Van DeWetering, M., Clevers, H., Pals, S.T., 2002. Wnt signal-
ing regulates expression of the receptor tyrosine kinase met in colorectal cancer. Can-
cer Res. 62, 5126–5128.
Brodsky, J.L., 2012. Cleaning up: ER-associated degradation to the rescue. Cell 151,
1163–1167.
Carmeliet, P., Jain, R.K., 2011. Molecular mechanisms and clinical applications of angio-
genesis. Nature 473, 298–307.
Carrillo De Santa Pau, E., Arias, F.C., Caso Pelaez, E., Munoz Molina, G.M., Sanchez
Hernandez, I., Muguruza Trueba, I., Moreno Balsalobre, R., Sacristan Lopez, S.,
Gomez Pinillos, A., Del Val Toledo Lobo, M., 2009. Prognostic signiﬁcance of the
expression of vascular endothelial growth factors A, B, C, and D and their recep-
tors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 115,
1701–1712.
Chaudhuri, A., Xie, M.H., Yang, B., Mahapatra, K., Liu, J., Marsters, S., Bodepudi, S.,
Ashkenazi, A., 2011. Distinct involvement of the Gab1 and Grb2 adaptor proteins in
signal transduction by the related receptor tyrosine kinases RON and MET. J. Biol.
Chem. 286, 32762–32774.
Chen, T.T., Luque, A., Lee, S., Anderson, S.M., Segura, T., Iruela-Arispe, M.L., 2010. Anchor-
age of VEGF to the extracellular matrix conveys differential signaling responses to en-
dothelial cells. J. Cell Biol. 188, 595–609.
Chong, C.R., Janne, P.A., 2013. The quest to overcome resistance to EGFR-targeted thera-
pies in cancer. Nat. Med. 19, 1389–1400.
Choura, M., Rebai, A., 2011. Receptor tyrosine kinases: from biology to pathology.
J. Recept. Signal Transduct. Res. 31, 387–394.
Cross, B.C., Bond, P.J., Sadowski, P.G., Jha, B.K., Zak, J., Goodman, J.M., Silverman, R.H.,
Neubert, T.A., Baxendale, I.R., Ron, D., Harding, H.P., 2012. The molecular basis for se-
lective inhibition of unconventional mRNA splicing by an IRE1-binding small mole-
cule. Proc. Natl. Acad. Sci. U. S. A. 109, E869–E878.
Dong, G., Chen, Z., Li, Z.Y., Yeh, N.T., Bancroft, C.C., Van Waes, C., 2001. Hepatocyte
growth factor/scatter factor-induced activation of MEK and PI3K signal path-
ways contributes to expression of proangiogenic cytokines interleukin-8 and
vascular endothelial growth factor in head and neck squamous cell carcinoma.
Cancer Res. 61, 5911–5918.
Duval, M., Bedard-Goulet, S., Delisle, C., Gratton, J.P., 2003. Vascular endothelial growth
factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination.
Consequences on nitric oxide production from endothelial cells. J. Biol. Chem. 278,
20091–20097.
Eder, J.P., Vande Woude, G.F., Boerner, S.A., Lorusso, P.M., 2009. Novel therapeutic inhib-
itors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 15, 2207–2214.
Ellis, L.M., Hicklin, D.J., 2008. VEGF-targeted therapy: mechanisms of anti-tumour activity.
Nat. Rev. Cancer 8, 579–591.
Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., Lindeman, N.,
Gale, C.M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A.J., Rogers, A.M., Cappuzzo, F.,
Mok, T., Lee, C., Johnson, B.E., Cantley, L.C., Janne, P.A., 2007. MET ampliﬁcation leads
to geﬁtinib resistance in lung cancer by activating ERBB3 signaling. Science 316,
1039–1043.
Ewan, L.C., Jopling, H.M., Jia, H., Mittar, S., Bagherzadeh, A., Howell, G.J., Walker, J.H.,
Zachary, I.C., Ponnambalam, S., 2006. Intrinsic tyrosine kinase activity is required
for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degrada-
tion in endothelial cells. Trafﬁc 7, 1270–1282.
Ferrara, N., Gerber, H.P., Lecouter, J., 2003. The biology of VEGF and its receptors. Nat. Med.
9, 669–676.
Forsythe, J.A., Jiang, B.H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D., Semenza, G.L., 1996.
Activation of vascular endothelial growth factor gene transcription by hypoxia-
inducible factor 1. Mol. Cell. Biol. 16, 4604–4613.
Gautier, L., Cope, L., Bolstad, B.M., Irizarry, R.A., 2004. affy—analysis of Affymetrix
GeneChip data at the probe level. Bioinformatics 20, 307–315.
Gavard, J., Gutkind, J.S., 2006. VEGF controls endothelial-cell permeability by promoting
the beta-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol. 8, 1223–1234.
Gherardi, E., Birchmeier, W., Birchmeier, C., Vande Woude, G., 2012. Targeting MET in
cancer: rationale and progress. Nat. Rev. Cancer 12, 89–103.
Glubb, D.M., Cerri, E., Giese, A., Zhang, W., Mirza, O., Thompson, E.E., Chen, P., Das, S.,
Jassem, J., Rzyman, W., Lingen, M.W., Salgia, R., Hirsch, F.R., Dziadziuszko, R.,
Ballmer-Hofer, K., Innocenti, F., 2011. Novel functional germline variants in the
VEGF receptor 2 gene and their effect on gene expression and microvessel density
in lung cancer. Clin. Cancer Res. 17, 5257–5267.
Goel, H.L., Mercurio, A.M., 2013. VEGF targets the tumour cell. Nat. Rev. Cancer 13,
871–882.
Gonzalvez, F., Lawrence, D., Yang, B., Yee, S., Pitti, R., Marsters, S., Pham, V.C., Stephan, J.P.,
Lill, J., Ashkenazi, A., 2012. TRAF2 Sets a threshold for extrinsic apoptosis by tagging
caspase-8 with a ubiquitin shutoff timer. Mol. Cell 48, 888–899.
Gordon, J.A., 1991. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor.
Methods Enzymol. 201, 477–482.
He, Z., Opland, D.M., Way, K.J., Ueki, K., Bodyak, N., Kang, P.M., Izumo, S., Kulkarni, R.N.,
Wang, B., Liao, R., Kahn, C.R., King, G.L., 2006. Regulation of vascular endothelial
growth factor expression and vascularization in the myocardium by insulin receptor
and PI3K/Akt pathways in insulin resistance and ischemia. Arterioscler. Thromb. Vasc.
Biol. 26, 787–793.
420 T.T. Chen et al. / EBioMedicine 2 (2015) 406–420Hetz, C., Glimcher, L.H., 2009. Fine-tuning of the unfolded protein response: assembling
the IRE1alpha interactome. Mol. Cell 35, 551–561.
Hirsch, C., Gauss, R., Horn, S.C., Neuber, O., Sommer, T., 2009. The ubiquitylation machin-
ery of the endoplasmic reticulum. Nature 458, 453–460.
Jiang, B.H., Zheng, J.Z., Aoki, M., Vogt, P.K., 2000. Phosphatidylinositol 3-kinase signaling
mediates angiogenesis and expression of vascular endothelial growth factor in endo-
thelial cells. Proc. Natl. Acad. Sci. U. S. A. 97, 1749–1753.
Khoury, H., Naujokas, M.A., Zuo, D., Sangwan, V., Frigault, M.M., Petkiewicz, S., Dankort,
D.L., Muller, W.J., Park, M., 2005. HGF converts ErbB2/Neu epithelial morphogenesis
to cell invasion. Mol. Biol. Cell 16, 550–561.
Kowanetz, M., Ferrara, N., 2006. Vascular endothelial growth factor signaling pathways:
therapeutic perspective. Clin. Cancer Res. 12, 5018–5022.
Lanahan, A.A., Hermans, K., Claes, F., Kerley-Hamilton, J.S., Zhuang, Z.W., Giordano, F.J.,
Carmeliet, P., Simons, M., 2010. VEGF receptor 2 endocytic trafﬁcking regulates arte-
rial morphogenesis. Dev. Cell 18, 713–724.
Lee, S., Chen, T.T., Barber, C.L., Jordan, M.C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos,
K.P., Iruela-Arispe, M.L., 2007. Autocrine VEGF signaling is required for vascular ho-
meostasis. Cell 130, 691–703.
Lichtenberger, B.M., Tan, P.K., Niederleithner, H., Ferrara, N., Petzelbauer, P., Sibilia, M.,
2010. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote ep-
ithelial cancer development. Cell 140, 268–279.
Liederer, B.M., Berezhkovskiy, L.M., Dean, B.J., Dinkel, V., Peng, J., Merchant, M., Plise, E.G.,
Wong, H., Liu, X., 2011. Preclinical absorption, distribution, metabolism, excretion,
and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-
ﬂuoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-ﬂuorophenyl)-
2-(4-ﬂuorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET ki-
nase inhibitor. Xenobiotica 41, 327–339.
Liu, Y., Chattopadhyay, N., Qin, S., Szekeres, C., Vasylyeva, T., Mahoney, Z.X., Taglienti, M.,
Bates, C.M., Chapman, H.A., Miner, J.H., Kreidberg, J.A., 2009. Coordinate integrin and
c-Met signaling regulate Wnt gene expression during epithelial morphogenesis. De-
velopment 136, 843–853.
Lu, K.V., Chang, J.P., Parachoniak, C.A., Pandika, M.M., Aghi, M.K., Meyronet, D., Isachenko,
N., Fouse, S.D., Phillips, J.J., Cheresh, D.A., Park, M., Bergers, G., 2012. VEGF inhibits
tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.
Cancer Cell 22, 21–35.
Lu, M., Lawrence, D.A., Marsters, S., Acosta-Alvear, D., Kimmig, P., Mendez, A.S., Paton,
A.W., Paton, J.C., Walter, P., Ashkenazi, A., 2014. Cell death. Opposing unfolded-
protein-response signals converge on death receptor 5 to control apoptosis. Science
345, 98–101.
Luque, A., Carpizo, D.R., Iruela-Arispe, M.L., 2003. ADAMTS1/METH1 inhibits endothelial
cell proliferation by direct binding and sequestration of VEGF165. J. Biol. Chem.
278, 23656–23665.
Pai, R., Dunlap, D., Qing, J., Mohtashemi, I., Hotzel, K., French, D.M., 2008. Inhibition of ﬁ-
broblast growth factor 19 reduces tumor growth by modulating beta-catenin signal-
ing. Cancer Res. 68, 5086–5095.
Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D.,
Kabbinavar, F., Slamon, D., 1999. Inhibitory effects of combinations of HER-2/neu an-
tibody and chemotherapeutic agents used for treatment of human breast cancers.
Oncogene 18, 2241–2251.Sadiq, A.A., Salgia, R., 2013. MET as a possible target for non-small-cell lung cancer. J. Clin.
Oncol. 31, 1089–1096.
Sawamiphak, S., Seidel, S., Essmann, C.L., Wilkinson, G.A., Pitulescu, M.E., Acker, T., Acker-
Palmer, A., 2010. Ephrin-B2 regulates VEGFR2 function in developmental and tumour
angiogenesis. Nature 465, 487–491.
Smith, N.R., Baker, D., James, N.H., Ratcliffe, K., Jenkins, M., Ashton, S.E., Sproat, G., Swann,
R., Gray, N., Ryan, A., Jurgensmeier, J.M., Womack, C., 2010. Vascular endothelial
growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vascula-
ture in human primary solid cancers. Clin. Cancer Res. 16, 3548–3561.
Soderberg, O., Gullberg,M., Jarvius, M., Ridderstrale, K., Leuchowius, K.J., Jarvius, J., Wester,
K., Hydbring, P., Bahram, F., Larsson, L.G., Landegren, U., 2006. Direct observation of
individual endogenous protein complexes in situ by proximity ligation. Nat. Methods
3, 995–1000.
Spigel, D.R., Ervin, T.J., Ramlau, R.A., Daniel, D.B., Goldschmidt Jr., J.H., Blumenschein Jr.,
G.R., Krzakowski, M.J., Robinet, G., Godbert, B., Barlesi, F., Govindan, R., Patel, T.,
Orlov, S.V., Wertheim, M.S., Yu, W., Zha, J., Yauch, R.L., Patel, P.H., Phan, S.C.,
Peterson, A.C., 2013. Randomized phase II trial of onartuzumab in combination
with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol.
31, 4105–4114.
Takeuchi, K., Ito, F., 2011. Receptor tyrosine kinases and targeted cancer therapeutics. Biol.
Pharm. Bull. 34, 1774–1780.
Turke, A.B., Zejnullahu, K., Wu, Y.L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L.,
Rogers, A., Mok, T., Sequist, L., Lindeman, N.I., Murphy, C., Akhavanfard, S., Yeap,
B.Y., Xiao, Y., Capelletti, M., Iafrate, A.J., Lee, C., Christensen, J.G., Engelman, J.A.,
Janne, P.A., 2010. Preexistence and clonal selection of MET ampliﬁcation in EGFR mu-
tant NSCLC. Cancer Cell 17, 77–88.
Vembar, S.S., Brodsky, J.L., 2008. One step at a time: endoplasmic reticulum-associated
degradation. Nat. Rev. Mol. Cell Biol. 9, 944–957.
Walter, P., Ron, D., 2011. The unfolded protein response: from stress pathway to homeo-
static regulation. Science 334, 1081–1086.
Wang, L., Perera, B.G., Hari, S.B., Bhhatarai, B., Backes, B.J., Seeliger, M.A., Schurer, S.C.,
Oakes, S.A., Papa, F.R., Maly, D.J., 2012. Divergent allosteric control of the IRE1alpha
endoribonuclease using kinase inhibitors. Nat. Chem. Biol. 8, 982–989.
Wilson, T.R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y.,
Sosman, J., Ribas, A., Li, J., Moffat, J., Sutherlin, D.P., Koeppen, H., Merchant, M., Neve,
R., Settleman, J., 2012. Widespread potential for growth-factor-driven resistance to
anticancer kinase inhibitors. Nature 487, 505–509.
Yamamoto, N., Mammadova, G., Song, R.X., Fukami, Y., Sato, K., 2006. Tyrosine phosphor-
ylation of p145met mediated by EGFR and Src is required for serum-independent
survival of human bladder carcinoma cells. J. Cell Sci. 119, 4623–4633.
Zhang, Y.W., Su, Y., Volpert, O.V., Vande Woude, G.F., 2003. Hepatocyte growth factor/
scatter factor mediates angiogenesis through positive VEGF and negative
thrombospondin 1 regulation. Proc. Natl. Acad. Sci. U. S. A. 100, 12718–12723.
Zhang, Z., Neiva, K.G., Lingen, M.W., Ellis, L.M., Nor, J.E., 2010. VEGF-dependent tumor an-
giogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell
Death Differ. 17, 499–512.
